Description du projet
Marquage au deutérium pour améliorer la spécificité et la sensibilité de l’imagerie par résonance magnétique dans le diagnostic du cancer
La tomographie par émission de positons (TEP) est la seule technologie établie pour l’imagerie moléculaire du corps entier, couramment utilisée pour le diagnostic du cancer et l’évaluation de son traitement. Cependant, la procédure TEP est coûteuse, implique des radiations ionisantes et affiche une spécificité limitée pour l’absorption de glucose associée au cancer. Le projet GLUCO-SCAN, financé par le CER, entend développer et évaluer un concept d’imagerie par résonance magnétique (IRM) du corps entier, tel que l’imagerie métabolique au deutérium (DMI), afin de surmonter les limites de la TEP actuelle. L’approche combinera du matériel IRM innovant, un échantillonnage dynamique de données spectroscopiques et des algorithmes d’apprentissage profond pour créer une nouvelle génération de scanners du corps entier capables de capturer simultanément des informations morphologiques et moléculaires.
Objectif
The targeted scientific breakthrough of GLUCO-SCAN is the development and clinical evaluation of a disruptive whole-body molecular imaging concept for cancer assessment. The only currently established whole-body molecular imaging device is positron emission tomography (PET). Glucose (Glc)-sensitive PET is widely used in cancer diagnosis and treatment assessment, but has several major limitations: PET involves harmful ionizing radiation, is expensive, not widely available, and cannot differentiate between cancer-specific and normal cellular glucose uptake. These limitations prohibit an even more widespread use of PET, e.g. for screening. We propose a new Magnetic Resonance Imaging (MRI) concept, whole-body deuterium metabolic imaging (DMI) that will overcome these limitations.
Deuteration is a simple chemical procedure with which it is possible to artificially label a broad range of molecules with an equally broad range of potential applications, e.g. targeting Glc metabolism in cancer. After ingestion, this labeled Glc is metabolized in cells and the label is transferred to all metabolic products, which can be tracked by DMI.
Building on our recent preliminary results in Nature Biomed, we propose a combination of novel MRI hardware, dynamic spectroscopic data sampling, deep learning algorithms, and a clinical validation to answer the following three research questions in a 5-year project:
(i) Is DMI a viable alternative for whole-body cancer assessment?
(ii) How is DMI positioned compared to Glc-sensitive PET?
(iii) Can DMI be performed on widely available MRI systems and simultaneous with standard MRI?
GLUCO-SCAN will fill a gap in current medical imaging by offering an alternative for whole-body PET examinations and potentially even for screening of high risk populations. Ultimately, it will pave the way for a new generation of MR scanners with all-in-one whole-body imaging capability that would capture morphologic and molecular information simultaneously.
Champ scientifique
Mots‑clés
Programme(s)
- HORIZON.1.1 - European Research Council (ERC) Main Programme
Régime de financement
HORIZON-ERC - HORIZON ERC GrantsInstitution d’accueil
1090 Wien
Autriche